Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...
Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...
Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a ...
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...
All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...
Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback